Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00520845
Recruitment Status : Terminated (slow accrual)
First Posted : August 27, 2007
Results First Posted : October 9, 2014
Last Update Posted : March 20, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Leora Horn, MD, Vanderbilt-Ingram Cancer Center

Tracking Information
First Submitted Date  ICMJE August 24, 2007
First Posted Date  ICMJE August 27, 2007
Results First Submitted Date  ICMJE October 5, 2014
Results First Posted Date  ICMJE October 9, 2014
Last Update Posted Date March 20, 2017
Study Start Date  ICMJE October 2007
Actual Primary Completion Date December 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 5, 2014)
Median Survival [ Time Frame: 2 years from date of registration ]
Estimated probable duration of life from on-study date to date of death from any cause, using the Kaplan-Meier method with censoring (see analysis population description for additional details)
Original Primary Outcome Measures  ICMJE
 (submitted: August 24, 2007)
Median Survival
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 5, 2014)
  • Overall Response Rate [ Time Frame: On-treatment date to date of disease progression (assessed at 6 weeks up to 2 years) ]
    Overall response rate is measured by complete response + partial response. Number of patients in each response category, per RECIST v1.1, summarized as follows for target lesion criteria (see RECIST v1.1 for additional details): complete response (CR),disappearance of target lesions; partial response (PR), >=30% decrease in sum of longest diameter of target lesions; progressive disease (PD), >=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD. Patients are categorized according to the best response achieved prior to occurrence of progressive disease, where best response hierarchy is CR>PR>SD>PD.
  • Time to Progression [ Time Frame: 2 years from date of registration ]
    Estimated probable duration from on-study date to date of disease progression, using the Kaplan-Meier method with censoring (see analysis population description for additional details). Disease progression is defined under RECIST v1.1 as >=20% increase in sum of longest diameters of target lesions, unequivocal progression of non-target lesions, or appearance of new lesions.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 24, 2007)
Time to Progression
Current Other Pre-specified Outcome Measures
 (submitted: October 5, 2014)
  • Effect of Celecoxib on Urinary Metabolites of PGE2, PG12 and Thromboxane [ Time Frame: At 1 year ]
  • Changes in Urinary PGE-M and Survival as Assessed by Immunohistochemistry [ Time Frame: At 1 year ]
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Official Title  ICMJE A Phase II Trial of Celecoxib Plus Chemotherapy [Docetaxel or Pemetrexed] in Patients With Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer
Brief Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving celecoxib together with docetaxel or pemetrexed may kill more tumor cells.

PURPOSE: This phase II trial is studying how well celecoxib given together with docetaxel or pemetrexed works in treating patients with advanced or recurrent non-small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

  • To determine the efficacy of celecoxib when administered with standard chemotherapy comprising docetaxel or pemetrexed disodium in patients with advanced, recurrent non-small cell lung cancer (NSCLC) exhibiting cyclooxygenase (COX) dependence.

Secondary

  • To determine the overall response rate and time to progression in patients with COX-dependent recurrent NSCLC treated with celecoxib and docetaxel or pemetrexed disodium.
  • To determine the effect of celecoxib on the urinary metabolites of PGE_2 , PGI_2, and thromboxane in patients with COX-dependent recurrent NSCLC.
  • To correlate changes in urinary PGE-M and survival with intratumoral expression of COX-2, mPGES, and 15-PGDH as assessed by IHC.

OUTLINE: Patients with no prior taxane exposure receive docetaxel IV over 1 hour on day 1; patients with prior taxane exposure or for whom docetaxel treatment is contraindicated receive pemetrexed disodium IV over 10 minutes on day 1. Treatment with docetaxel or pemetrexed disodium repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral celecoxib twice daily beginning 5-7 days prior to the first docetaxel or pemetrexed disodium infusion and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.

Patients undergo blood and urine sample collection at baseline and periodically during study for biomarker correlative studies. Urine samples are assessed for PGE-M levels. Blood samples are analyzed for serum celecoxib levels, VEGF, endostatin, and cytokine assays.

After completing the last dose of celecoxib, patients are followed at 4-6 weeks and then every 3 months thereafter for up to 2 years from study entry.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lung Cancer
Intervention  ICMJE
  • Drug: celecoxib
    600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
  • Drug: Docetaxel
    75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
  • Drug: pemetrexed disodium
    500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
  • Other: laboratory biomarker analysis
    Blood collection
Study Arms  ICMJE Experimental: Treatment Arm
Either docetaxel or pemetrexed given with celecoxib
Interventions:
  • Drug: celecoxib
  • Drug: Docetaxel
  • Drug: pemetrexed disodium
  • Other: laboratory biomarker analysis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: October 5, 2014)
23
Original Enrollment  ICMJE
 (submitted: August 24, 2007)
74
Actual Study Completion Date  ICMJE January 2014
Actual Primary Completion Date December 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Eligibility Criteria:

  • Cytologically or histologically confirmed "COX dependent" non-small cell lung cancer.
  • COX dependency is defined by change in urinary PGE-M levels following a "run-in" phase of celecoxib.
  • Previous treatment with ≤2 different chemotherapy regimens one of which must have been platinum-based (cisplatin or carboplatin) chemotherapy.
  • Age ≥18 years
  • ECOG PS 0, 1 or 2.
  • Measurable or evaluable disease.
  • At least 3 weeks post major surgery, chemotherapy or radiotherapy & recovered from all toxicities.
  • Expected survival of at least 2 months.
  • CNS metastases permitted provided the patient has adequately recovered from radiotherapy includes stereotactic therapy) or surgery.
  • Adequate renal function: serum creatinine ≤1.8 mg/dl &/or CrCl >50 cc/min

Eligibility According to Liver Function:

AST:

</= 1.5 ULN-Docetaxel; </= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); </= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

Alk Phosphatase:

</= 2.5 ULN-Docetaxel; </= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); </= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

Total Bilirubin:

</= 1.5 ULN-Docetaxel; </= 1.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); </= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

  • Adequate hematologic function: ANC≥1500/mm3 & platelets ≥100,000/mm3
  • Female patients cannot be pregnant and must use contraception if of childbearing age
  • Lactating women are excluded.
  • Peripheral neuropathy must be CTC grade ≤2
  • Patients must not currently be on non-steroidal anti-inflammatory agents or other COX-2 inhibitors (Must be off for at least ≤7 days)
  • Written informed consent.

Exclusion Criteria:

  • More than two prior chemotherapy regimens for recurrent or relapsed NSCLC.
  • COX Independent as defined by change in urinary PGE-M levels following a "run-in" phase of celecoxib.
  • Previous treatment with both docetaxel and pemetrexed
  • History of greater than grade 2 allergic reaction to celecoxib or any other non-steroid anti-inflammatory agent including aspirin, ibuprofen, or indomethacin.
  • History of allergy to compounds containing boron or mannitol.
  • History of allergy to sulfonamides.
  • Concomitant use of Warfarin, but low dose Coumadin allowed for port prophylaxis
  • Recent (past 4 weeks) coronary artery bypass graft (CABG) surgery.
  • Inadequate organ function:
  • Serum creatinine ≥1.8 mg/dl or a calculated CrCl <45 cc/min.
  • AST >1.5 upper limits of normal (ULN); alkaline phosphatase >2.5 ULN; & bilirubin >1.5 ULN
  • ANC<1500/mm3 & platelets <100,000/mm3
  • Active pregnancy or inability or unwillingness to employ appropriate contraception.
  • Small cell carcinoma histology.
  • Prior malignancy within 5 years of diagnosis of NSCLC. Exceptions include basal cell or non-metastatic squamous cell carcinomas of the skin, cervical carcinoma in situ or FIGO stage I cervical carcinoma, or other cancer history considered not clinically significant by the principal investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00520845
Other Study ID Numbers  ICMJE VICC THO 0730
P30CA068485 ( U.S. NIH Grant/Contract )
VU-VICC-THO-0730
VU-VICC-IRB-070723
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Leora Horn, MD, Vanderbilt-Ingram Cancer Center
Study Sponsor  ICMJE Vanderbilt-Ingram Cancer Center
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Leora Horn, MD Vanderbilt-Ingram Cancer Center
PRS Account Vanderbilt-Ingram Cancer Center
Verification Date February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP